2016


To access this material please log in or register

Register Authorize
2016/№4

Role of vaccine antigens against influenza and pneumococcal infection in pathogenesis of chronic cardiovascular diseases

Pakhomov D.V.1, Arutyunov G.P.2, Kostinov M.P.1
1 – Federal State Budgetary Science Institution, “I.I. Mechnikov Research Institute of Vaccines and Sera” of the Russian Academy of Sciences, Malyi Kazennyi Per. 5A, Moscow 105064
2 – State Budgetary Educational Institution of Higher Professional Education, "N.I. Pirogov Russian National Research Medical University " of the RF Ministry of Health Care, Ostrovityanova 1, Moscow 117997

Keywords: vaccination, cardiovascular diseases, mortality

DOI: 10.18087/rhfj.2016.4.2244

The review presents studies focusing on effects of anti-influenza and antipneumococcal vaccination on cardiovascular diseases and mortality.
1. Оганов Р.Г., Концевая А.В., Калинина А.М. Экономический ущерб от сердечно-сосудистых заболеваний в Российской Федерации. Кардиоваскулярная терапия и профилактика. 2011;10(4):4-9 [Oganov R.G., Konczevaya A.V., Kalinina A.M. E`konomicheskij ushherb ot serdechno-sosudisty`x zabolevanij v Rossijskoj Federaczii. Kardiovaskulyarnaya terapiya i profilaktika. 2011;10 (4):4–9].
2. Ревич Б.А. Изменение здоровья населения России в условиях меняющегося климата. Проблемы прогнозирования. 2008;3:140—50 [Revich B.A. Izmenenie zdorov`ya naseleniya Rossii v usloviyax menyayushhegosya klimata. Problemy` prognozirovaniya. 2008;3:140–50].
3. Collins SD. Excess mortality from cases other than influenza and pneumonia during influenza epidemic. Pub Health Rep. 1932;47:2159-79.
4. Pesonen E, Siitonen O. Acute myocardial infraction precipitated by infectious diseases. Am Heart J. 1981 Apr;101(4):512-3.
5. Tillett HE, Smith JW, Gooch CD. Excess deaths attributable to influenza in England and Wales: age at deaths and certified cause. Int J Epidemiol. 1983 Sep;12(3):344-52.
6. Бойцов С.А., Лукьянов М.М., Платонова Е.В., Горбунов В.М., Романчук С.В., Назарова О.А. и др. Исследование эффективности и безопасности вакцинопрофилактики гриппа у пациентов с болезнями системы кровообращения. Профилактическая медицина. 2014;17(6):13-20 [Bojczov S.A., Luk`yanov M. M., Platonova E.V., Gorbunov V.M., Romanchuk S.V., Nazarova O.A. i dr. Issledovanie e`ffektivnosti i bezopasnosti vakczinoprofilaktiki grippa u paczientov s boleznyami sistemy` krovoobrashheniya. Profilakticheskaya mediczina. 2014;17 (6):13–20].
7. Spodick DH, Flessas AP, Johnson MM. Association of acute respiratory symptoms with onset of acute myocardial infarction: prospective investigation of 150 consecutive patients and matched control patients. Am J Cardiol. 1984 Feb 1;53(4):481—2.
8. Sprenger MJ, Mulder PG, Beyer WE, Van Strik R, Masurel N. Impact of influenza on mortality in relation to age and underlying disease, 1967-1989. Int J Epidemiol. 1993 Apr;22(2):334—40.
9. Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. New Engl J Med. 2003 Apr 3;348(14):1322—32.
10. Pinol-Ripoll G, de la Puerta I, Santos S, Purroy F, Mostacero E. Chronic bronchitis and acute infections as new risk factors for ischemic stroke and the lack of protection offered by the influenza vaccination. Cerebrovasc Dis. 2008;26(4):339—47.
11. Lavallée P, Perchaud V, Gautier-Bertrand M, Grabli D, Amarenco P. Association between influenza vaccination and reduced risk of brain infarction. Stroke. 2002 Feb;33(2):513—8.
12. Phrommintikul A, Kuanprasert S, Wongcharoen W, Kanjanavanit R, Chaiwarith R, Sukonthasarn A. Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome. Eur Heart J. 2011 Jul;32(14):1730—5.
13. Binder CJ, Horkko S, Dewan A, Chang MK, Kieu EP, Goodyear CS et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med. 2003 Jun;9(6):736—43.
14. Meyers DG. Myocardial infarction, stroke, and sudden cardiac death maybe prevented by influenza vaccination. Curr Atheroscler Rep. 2003 Mar;5(2):146—9.
15. Naghavi M, Barlas Z, Siadaty S, Naguib S, Madjid M, Casscells W. Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation. 2000 Dec 19;102(25):3039—45.
16. Hung IF, Leung AY, Chu DW, Leung D, Cheung T, Chan CK et al. Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: a prospective cohort study. Clin Infect Dis. 2010 Nov 1;51(9):1007—16.
17. Udell JA, Zawi R, Bhatt DL, Keshtkar-Jahromi M, Gaughran F, Phrommintikul A et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA. 2013 Oct 23;310(16):1711-20.
18. Osterhaus A, Fouchier R, Rimmelzwaan G. Towards universal influenza vaccines? Philos Trans R Soc Lond B Biol Sci. 2011 Oct 12;366(1579):2766-73.
19. Veljkovic N, Glisic S, Prljic J, Perovic V, Botta M, Veljkovic V. Discovery of new therapeutic targets by the informational spectrum method. Curr Protein Pept Sci. 2008 Oct;9(5):493-506.
20. Nwanko N, Seker H. Digital signal processing techniques: calculating biological functionalities. J Proteomics Bioinform. 2011;4(12):260-8.
21. Veljkovic V, Veljkovic N, Muller CP, Müller S, Glisic S, Perovic V, Kőhler H. Characterization of converved properties of hemagglutinin of H5N1 and human influenza viruses: possible consequences for therapy and infection control. BMC Struct Biol. 2009 Apr 7;9:21.
22. Veljkovic V, Niman HL, Glisic S., Veljkovic N, Perevic V, Muller CP. Identification of hemagglutinine structural domain and polymorphisms which may modulate swine H1N1interactions with human receptor. BMC Struct Biol. 2009 Sep 28;9:62.
23. Veljkovic V, Glisic S, Veljkovic N, Bojic T, Dietrich U, Perovic VR, Colombatti A. Influenza vaccine as prevention for cardiovascular diseases: possible molecular mechanism. Vaccine. 2014 Nov 12;32(48):6569-75.
24. Muscari C, Bonafe F, Giordano E, Tantini B, Fattori M, Guarnieri C, Caldarera CM. Early preconditioning prevents the loss of endothelial nitric oxide synthase and enhances its activity in the ischemic/reperfused rat heart. Life Sci. 2004 Jan 16;74(9):1127-37.
25. Xuan YT, Guo Y, Zhu Y, Wang OL, Rokosh G, Bolli R. Endothelial nitric oxide synthase plays an obligatory role in the late phase of ischemic preconditioning by activating the protein kinase C epsilon p44/42 mitogen-activated protein kinase pSer-signal transducers and activates transcription 1/3 pathway. Circulation. 2007 Jul 31;116(5):535-44.
26. Hausenloy DJ, Yelon DM. Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res. 2006 May 1;70(2):240-53.
27. Li XD, Cheng YT, Yang YJ, Meng XM, Zhao JL, Zhang HT et al. PKA-mediated eNOS phosphorylation in the protection of ischemic preconditioning against no-reflow. Microvasc Res. 2012 Jul;84(1):44-54.
28. Ju H, Venema VJ, Marrero MB, Venema RC. Inhibitory interactions of the bradykinin B2 receptor with endothelial nitric-oxide synthase. J Biol Chem. 1998 Sep 11;273(37):24025-9.
29. Golser R, Gorren AC, Leber A, Andrew P, Habisch HJ, Werner ER et al. Interaction of endothelial and neuronal nitric oxide synthases with the bradykinin B2 receptor, binding of an inhibitory peptide to the oxygenase domain blocks uncoupled NADPH oxidation. J Biol Chem. 2000 Feb 25;275(8):5291-6.
30. Thomas PS, Ng C, Elsing M, Yates DH. Influenza vaccination: challenges in exhaled nitric oxide levels and sputum cytology. Respirology. 1999 Dec;4(4):355-8.
31. Mashir A, Paschke KM, van Duin D, Shrestha NK, Laskowski D, Storer MK et al. Effect of influenza A (H1N1) live attenuated intranasal vaccine on nitric oxide (FENO) and other volatiles in exhalted breath. J Breath Res. 2011 Sep;5(3):037107.
32. Murphy AW, Platts-Mills TA, Lobo M, Hayden F. Respiratory nitric oxide levels in experimental human influenza. Chest. 1998 Aug;114(2):452-6.
33. Vrints H, Shivalkar B, Hilde H, Vanderveken OM, Hamans E, Van de Heyning P et al. Cardiovascular mechanisms and consequences of obstructive sleep apnoea. Acta Clin Belg. 2013 May-Jun;68(3):169-78.
34. Taylor FC, Huffman M, Ebrahim S. Statin therapy for primary prevention of cardiovascular disease. JAMA. 2013 Dec 11;310(22):2451–2.
35. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002 Jul 6;360(9326):7–22.
36. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006 Aug 10;355(6):549–59.
37. Bu DX, Griffin G, Lichtman AH. Mechanisms for the anti-inflammatory effects of statins. Curr Opin Lipidol. 2011 Jun;22(3):165–70.
38. Weitz-Schmidt G,Welzenbach K, Brinkmann V, Kamata T, Kallen J, Cottens S et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med. 2001 Jun;7(6):687–92.
39. Han KH, Ryu J, Hong KH, Ko J, Pak YK, Kim JB et al. HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo. Circulation. 2005 Mar 22;111(11):1439–47.
40. Ghittoni R, Napolitani G, Benati D, Ulivieri C, Patrussi L, Laghi Pasini F et al. Simvastatin inhibits the MHC class II pathway of antigen presentation by impairing Ras superfamily GTPases. Eur J Immunol. 2006 Nov;36(11):2885–93.
41. Bessler H, Salman H, Bergman M, Straussberg R, Djaldetti M. In vitro effect of statins on cytokine production and mitogen response of human peripheral blood mononuclear cells. Clin Immunol. 2005 Oct;117(1):73–7.
42. Ghittoni R, Patrussi L, Pirozzi K, Pellegrini M, Lazzerini PE, Capecchi PL et al. Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases. FASEB J. 2005 Apr;19(6):605–7.
43. Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002 Nov 7;420(6911):78–84.
44. Jameson JM, Cruz J, Costanzo A, Terajima M, Ennis FA. A role for the mevalonate pathway in the induction of subtype cross-reactive immunity to influenza A virus by human gammadelta T lymphocytes. Cell Immunol. 2010;264(1):71–7.
45. Black S, Nicolay U, Del Giudice G, Rappuoli R. The influence of statins on influenza vaccine response in the elderly. J Infect Dis. 2016 Apr 15;213(8):1224-8.
46. Omer SB, Phadke VK, Bednarczyk RA, Chamberlain AT, Brosseau JL, Orenstein WA. Impact of statins on influenza vaccine effectiveness against medically attended acute respiratory illness. J Infect Dis. 2016 Apr 15;213(8):1216-23.
47. Nguyen JT, Myers N, Palaia J, Georgopoulos A, Rubins JB, Janoff EN. Humoral responses to oxidized low-density lipoprotein and related bacterial antigens after pneumococcal vaccine. Transl Res. 2007 Sep;150(3):172-9.
48. Madjid M, Naghavi M, Litovsky S, Casscells SW. Influenza and cardiovascular disease: a new opportunity for prevention and the need for further studies. Circulation. 2003 Dec 2;108(22):2730—6.
Pakhomov D.V., Arutyunov G.P., Kostinov M.P. Role of vaccine antigens against influenza and pneumococcal infection in pathogenesis of chronic cardiovascular diseases. Russian Heart Failure Journal. 2016;17 (4):287–290

To access this material please log in or register

Register Authorize
Ru En